Reproducibility has always been a serious challenge when medical researchers in both academia and industry have tried to build upon previously published discoveries. Blindly chasing faulty results has incurred a huge waste of human and monetary resources. The damage to the progress of scientific discoveries, as well as their application to human well-being, cannot be overestimated. According to two reports by Bayer and Amgen published in 2011 and 2012, 64e89% of the socalled "landmark" results could not be reproduced in their pre-clinical validation experiments.
